Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases
The outcome of 221 patients with bulky (≥10 cm) classic Hodgkin lymphoma (cHL) treated with doxorubicin, bleomycin, vinblastine, dacarbazine and consolidative radiotherapy (RT) only in those with a positive end-of-treatment (EOT) positron emission tomography (PET) scan was evaluated. With a median follow-up of 9.6 years, 5- and 10-year progression-free survival (PFS) in EOT PET-negative cases were 94.0% and 90.4%, respectively, and in PET-positive cases, 5/10-year PFS was 64.6% (p < 0.001), with 15% overall receiving RT. Five-year PFS for Deauville (D) score DX/D1-3 was 93.6%, compared with D4 66.7% (p < 0.001) and D5 33.3% (p < 0.001). Omission of RT in EOT PET-negative cases is associated with excellent long-term outcomes in bulky cHL.
Authors
- Alina S. Gerrie (ORCID: https://orcid.org/0000-0003-4727-1425)
- Pedro Farinha (ORCID: https://orcid.org/0000-0001-9364-9391)
- Kerry J. Savage (ORCID: https://orcid.org/0000-0002-5835-9863)
- Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
- Chris Venner
- Jowon L. Kim (ORCID: https://orcid.org/0000-0002-7008-2035)
- François Bénard (ORCID: https://orcid.org/0000-0001-7995-3581)
- Danielle Wilson
- Diego R. Villa (ORCID: https://orcid.org/0000-0002-4625-3009)
- David W. Scott (ORCID: https://orcid.org/0000-0003-4918-2610)
- Graham W. Slack (ORCID: https://orcid.org/0000-0001-9132-3611)
- Brian Skinnider
- R. Petter Tonseth (ORCID: https://orcid.org/0000-0002-2712-7189)
- Andrea Lo (ORCID: https://orcid.org/0000-0002-3253-1071)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Spinal Cord Injury BC (CA)
- ABT Molecular Imaging (United States) (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1111/bjh.19859
- Citations
- 3
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- AstraZeneca
- Regeneron Pharmaceuticals
- BeiGene
- Veracyte
- Seagen
- Loxo Oncology